SCHEMBL5059236

SCHEMBL5059236

Cn1c(N)c(NC(=O)c2c[nH]nc2Cc2cccc(F)c2)c(=O)n(CC2CC2)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.42
ADORA2B P29275 3/20 0.42
ADORA1 P30542 3/20 0.42
ADORA3 P0DMS8 2/20 0.42
MAPT P10636 3/20 0.39
CYP3A4 P08684 2/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
ADRA1B P35368 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
DHODH Q02127 1/20 0.37
PARP1 P09874 3/20 0.35
MET P08581 1/20 0.35
AXL P30530 1/20 0.35
LMNA P02545 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5597238 0.91 ADORA3 (0.44) ADORA2AADORA2BADORA1ADORA3MAPT
SCHEMBL5597387 0.90 ADORA2A (0.39) ADORA2AADORA2BADORA1ADORA3MAPT
SCHEMBL1546111 0.77 ADORA2A (0.55) ADORA2AADORA2BADORA1ADORA3
SCHEMBL5054303 0.72 ADORA2B (0.42) ADORA2AADORA2BADORA1ADORA3MAPT
SCHEMBL1546006 0.69 ADORA2B (0.57) ADORA2AADORA2BADORA1ADORA3
SCHEMBL1546706 0.69 ADORA2B (0.49) ADORA2AADORA2BADORA1ADORA3TP53
SCHEMBL1546538 0.68 ADORA2A (0.51) ADORA2AADORA2BADORA1ADORA3MAPT
SCHEMBL6856480 0.67 HCAR2 (0.54) PARP1
SCHEMBL1546772 0.66 KLKB1 (0.49) ADORA2AADORA2BADORA1ADORA3BRD4
SCHEMBL1546750 0.66 ADORA2B (0.52) ADORA2AADORA2BADORA1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996201-A2 METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2008-12-03 EP disclosed
WO-2007109547-A2 METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2007-09-27 WO disclosed